Mark your calendars!
We are bringing you a LIVE Men's Panel to talk about Men's Health! You can find us on here on Youtube A Cure in Sight (be sure to subscribe!) or on our Facebook Page!
Saturday, Nov 16th at 3:30pm PST/ 6:30pm EDT
Hope to see you there!
2 - 0
Listen now on Facebook! www.facebook.com/share/v/1YPGMTLMk3gvHvCw/?mibexti…
Hope is on the Horizon with Dr. Shields!
Please help us share this video to spread the hope in #ocularmelanoma
Legend Dr. Shields discloses the importance of early detection, advances in research, and helps you understand YOUR brand of #uvealmelanoma
Got questions? Share below and let us know so we can bring her back to bring you more of what you'd like to know!
Special thanks to sponsor Castle Biosciences, Inc. for making this podcast and video channel possible - please consider a donation to help us continue bringing valuable content to the ocular melanoma community.
2 - 0
2 - 0
Join us LIVE on the Facebook Page or Youtube to chat with psychologist Maureen Sanger.
"Protecting your Mental Health: Navigating a Rare Cancer Diagnosis"
March 31, 2023
5:00PM-5:30PM EST
Maureen Sanger, PhD is a psychologist with Tennessee Oncology providing counseling to cancer patients and survivors. She received her doctorate in clinical psychology from Vanderbilt University and trained at MD Anderson Cancer Center. Prior to joining Tennessee Oncology she was an Assistant Professor of Pediatrics at Vanderbilt University Medical Center where she worked with the cancer and sickle cell disease programs.
Come prepared with questions on navigating initial diagnosis as well as mets.
See you Friday!
1 - 0
Stay tuned this week for a chat with Dr. Meredith McKean, a medical oncologist who spoke recently at Eye Believe 2022.
Date: February 7, 10:00am MST/9:00am PST / 12:00pm CST
Where: live on Facebook and YouTube Channels
Topic: Systemic Therapy 101: when to use systemic therapies, what is out there besides KIMMTRAK, how to determine a path forward for introducing systemic therapies in metastatic management
McKean received her bachelor's degree from Iowa State University, where the promising athlete ran cross-country and track. During fellowship, McKean studied biomarkers for response to immune checkpoint inhibitors (ICI) in metastatic melanoma, earning her an American Society of Clinical Oncology 2017 Young Investigator Award. She now serves as the director for the Melanoma and Skin Cancer Research Program at the Sarah Cannon Research Institute at Tennessee Oncology.
Excited for this conversation! Be sure to mark your calendars and join us live
1 - 0
We are always thrilled as a patient advocacy group to see news like this! Thank you for this advancement for #uvealmelanoma patients IDEAYA Biosciences
From their press release this morning:
"IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has initiated enrollment into a company-sponsored Phase 2 clinical trial to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients. The company also provided guidance for an update on its Phase 2 clinical trial evaluating darovasertib in combination with crizotinib in metastatic uveal melanoma (MUM) patients in 2023.
"We are excited to clinically evaluate darovasertib as a neoadjuvant and an adjuvant treatment in uveal melanoma patients. This is a paradigm-shifting opportunity, as there are no approved systemic therapies in these settings. The preliminary clinical data shows clear evidence of anti-tumor activity and supports further clinical evaluation of darovasertib to determine its potential to either save the eye by avoiding enucleation, or to reduce the tumor thickness in the eye, enabling treatment with less radiation to preserve vision," said Dr. Carol Shields, M.D., Chief, Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.
"The primary tumor shrinkage we are observing from just a single month of therapy in our investigator-sponsored NADOM study is very promising. We are looking forward to seeing even greater benefits in the IDEAYA-sponsored Phase 2 study where the protocol provides for neoadjuvant treatment to maximum response," said Professor Anthony Joshua, MBBS, PhD, FRACP, Head Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital Sydney. "
bit.ly/3kA36h9
1 - 0
Faces of OM 3.0 has arrived! SHARE in your groups and tag omies below!
We're compiling our 3rd Faces of OM video--showing the faces of #ocularmelanoma
Follow the directions and submit at the form below! DEADLINE TO SUBMIT = Feb 1 by midnight!
acureinsight.wufoo.com/forms/r1o511u40j6rofw/
2 - 0
January is #mentalwellnessmonth and we are pleased to announce our 2nd annual Eye on Mental Health Mini-Seminar. Register below!
Register at tinyurl.com/eyeonmentalhealth23
Many thanks to our sponsors for their involvement to make this seminar possible!
1 - 0
A Cure In Sight provides information and education on Ocular Melanoma also known as uveal melanoma and conjunctival melanoma. Visit our website at acureinsight.org for more information and resources.